What changed from existing technology?
This study looked at how a drug called dihydroartemisinin might help treat lung cancer that doesn't respond to other medicines by changing a specific protein involved in cancer cell growth and death.
This study is the first to show that dihydroartemisinin can target AURKA to overcome drug resistance in non-small cell lung cancer, revealing a new mechanism for treating resistant cancers.
Commercialization signals visible at publication
This is not a success probability or investment opinion. It prioritizes follow-up using evidence available when the paper was published.
Verified evidence · 1
AURKA modulation. Non-small cell lung cancer (NSCLC) remains the leading cause of cancer-related mortality globally, with acquired chemoresistance posin
Abstract ↗- 시제품·장치 구현 근거 미확인
- 제조·규모 확장 근거 미확인
- 장기·실사용 검증 근거 미확인
Later patent, company, clinical, and production events are added separately only after verification.
Patent check: Not checked yetCurrent technology stage: Early research
See what changed before reading the full paper.
What still needs to be solved?
Repeated real-world validation, manufacturability, cost, and long-term stability still require follow-up evidence.
What could change if this succeeds?
Dihydroartemisinin may be a potential therapeutic option for drug-resistant non-small cell lung cancer by targeting AURKA, though further clinical studies are needed to confirm its efficacy.
Keep following this technology
Revisit changes when new papers, patents, company participation, validation, or products appear.